Selected References
- Obergfäll, D., Hahn, F., Kicuntod, J., Wangen, C., Kögler, M., Wagner, S., Kaufer, B. & Marschall, M. (2025). New assay systems to characterize the broad-spectrum antiherpesviral and non-herpesviral activity of cyclin-dependent kinase (CDK) 8 inhibitors. Pharmaceuticals 18: 1560, doi: 10.3390/ph18101560, PMID: 41155676.
- Dhotre, K., Schütz, M., von Essen, S., Fortelny, L., Wangen, C., Hahn, F., Sticht, H. & Marschall, M. (2025). Conserved mode of nuclear lamina distortion by primate cytomegaloviruses: importance of the pSer22 motif, viral kinase, and cis/trans isomerase Pin1 activity. J. Gen. Virol. 106: 002160, doi: 10.1099/jgv.0.002160, PMID: 41171811.
- Tillmanns, J., Battisti, V., Kicuntod, J. Hahn, F., Obergfäll, D., Geiger, P., Wagner, S., Buschmann, H., Lesch, B., Lischka, P., Sticht, H., Langer, T. & Marschall, M. (2025). The conserved core nuclear egress complex (NEC) as an antiherpesviral drug target: pharmacophore-based identification of NEC-specific inhibitors. Antiviral Res. 106168, doi: 10.1016/j.antiviral.2025.106168, PMID: 40250630.
- Obergfäll, D.*, Wild, M.*, Sommerer, M., Barillas Dahm, M., Kicuntod, J., Tillmanns, J., Kögler, M., Lösing, J., Dhotre, K., Müller, R., Wangen, C., Wagner, S., Phan, Q.V., Wiebusch, L., Briestenská, K., Mistríková, J., Kerr-Jones, L., Stanton, R.J., Voigt, S., Hahn, F. & Marschall, M. (2024). Cyclin-dependent kinase 8 represents a positive regulator of cytomegalovirus replication and a novel host target for antiviral strategies. Pharmaceutics 16: 1238, doi: org/10.3390/pharmaceutics16091238, PMID: 39339274 (*contributed equally).
- Marschall, M., Schütz, M.*, Wild, M.*, Socher, E., Wangen, C., Dhotre, K., Rawlinson, W.D. & Sticht, H. (2024). Understanding the cytomegalovirus cyclin-dependent kinase ortholog pUL97 as a multifaceted regulator and an antiviral drug target. Cells 13: 1338, doi: org/10.3390/cells13161338, PMID: 39195228 (*contributed equally)
- Tillmanns, J.*, Kicuntod, J.*, Ehring, A.*, Elbasani, E., Borst, E.M., Obergfäll, D., Müller, R., Hahn, F. & Marschall, M. (2024a). Establishment of a luciferase-based reporter system to study aspects of human cytomegalovirus infection, replication characteristics, and antiviral drug efficacy. Pathogens, 13: 645, doi: org/10.3390/pathogens13080645doi, PMID: 39204245 (*contributed equally).
- Tillmanns, J.*, Kicuntod, J.*, Lösing, J. & Marschall, M. (2024b). 'Getting Better'—Is it a feasible strategy of broad pan-antiherpesviral drug targeting by using the nuclear egress-directed mechanism? Int. J. Mol. Sci. 25: 2823, doi: org/10.3390/ijms25052823, PMID: 38474070 (*contributed equally) #.
- Yu, D.H.*, Wagner, S.*, Schütz, M., Jeon, Y., Seo, M., Kim, J., Brückner, N., Kicuntod, J., Tillmanns, J., Wangen, C., Hahn, F., Kaufer, B.B., Neipel, N., Eickhoff, J., Klebl, B., Nam, K. & Marschall, M. (2024) An antiherpesviral host-directed strategy based on CDK7 covalently binding drugs: target-selective, picomolar-dose, cross-virus reactivity. Pharmaceutics 16: 158, doi: org/10.3390/pharmaceutics16020158, PMID: 38399219 (*contributed equally).
- Egilmezer, E., Hamilton, S.T., Foster, C.S.P., Marschall, M. & Rawlinson, W.D. (2024). Human cytomegalovirus (CMV) dysregulates neurodevelopmental pathways in cerebral organoids. Commun. Biol. 7: 340, doi: 10.1038/s42003-024-05923-1, PMID: 38504123.
- Gege, C., Hahn, F., Wangen, C., Häge, S., Herrmann, A., Uhlig, N., Eberlein, V., Issmail, L., Klopfleisch, R., Grunwald, T., Marschall, M., Kohlhof, H. & Vitt, H. (2024). Synthesis and characterization of DHODH inhibitors based on the vidofludimus scaffold with pronounced anti-SARS-CoV-2 activity. ChemMedChem - Chemistry Europe, 18: e202400292, doi: 10.1002/cmdc.202400292, PMID: 38887198.
